TrialNeuro-oncology2026

Phase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas.

David Schiff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.